Read more:

Wednesday, February 27, 2013 Publishes PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022

mrrbiz180x180PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022


GlobalData has released its new Country report, PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCBs Keppra and GlaxoSmithKlines Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizers Dilantin, Abbotts Depakote, and Novartis Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKlines Trobalt/Potiga and Eisais Fycompa which both offer first-in-class mechanisms of action.
To Buy The Copy Of This Report Visit:

The main driver for growth in this market is the launch of new AEDs with novel MOAs and the lower-than-average rate of generic substitution in France compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.


- Overview of Epilepsy including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting France Epilesy market.
To Read The Complete Report with TOC Kindly Visit:

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in France

For More Information Contact:
Hemendra Parmar
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030

No comments:

Post a Comment